Recursion Pharmaceuticals (RXRX) insider schedules 30,000-share Class A stock sale

Rhea-AI Filing Summary

Recursion Pharmaceuticals Inc. insider Blake C. Borgeson filed to sell up to 30,000 Class A shares of RXRX through Fidelity Brokerage Services, with a proposed aggregate sale price of $97,500.00 on August 4, 2026. The shares are identified as founders shares acquired from the issuer as compensation on September 19, 2017. The filing also lists prior Class A share sales over the past three months: 30,000 shares for $105,600.00 on May 5, 2026, 30,000 shares for $110,400.00 on June 2, 2026, and 40,000 shares for $158,500.00 on July 7, 2026.

Key Figures

Planned shares to be sold: 30,000 shares Proposed aggregate sale price: $97,500.00 Shares sold May 5, 2026: 30,000 shares +5 more

8 metrics

Planned shares to be sold 30,000 shares Class A shares proposed for sale via Fidelity on August 4, 2026

Proposed aggregate sale price $97,500.00 Estimated total for 30,000 Class A shares on August 4, 2026

Shares sold May 5, 2026 30,000 shares Class A shares sold for $105,600.00 on May 5, 2026

Proceeds May 5, 2026 $105,600.00 Aggregate amount for 30,000 Class A shares sold

Shares sold June 2, 2026 30,000 shares Class A shares sold for $110,400.00 on June 2, 2026

Shares sold July 7, 2026 40,000 shares Class A shares sold for $158,500.00 on July 7, 2026

Total recent shares sold 100,000 shares Sum of past three months’ Class A share sales reported

Total recent sale proceeds $374,500.00 Aggregate proceeds from past three months’ Class A share sales

Key Terms

Form 144, founders shares, compensation

3 terms

Form 144 regulatory

"Blake C. Borgeson is reporting planned and recent sales under Form 144"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

founders shares financial

"Class A | 09/19/2017 | Founders Shares | Issuer |"

Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.

compensation financial

"30000 | 09/19/2017 | Compensation"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/04/2026 - 01:37 PM Accepted by SEC EDGAR 08/04/2026 - 01:37 PM Learn about SEC filing dates

FAQ

What insider sale is disclosed for RXRX in this Form 144?

Blake C. Borgeson filed to potentially sell 30,000 Class A shares of Recursion Pharmaceuticals Inc. with a proposed aggregate sale price of $97,500.00, to be executed through Fidelity Brokerage Services on August 4, 2026.

Who is the selling security holder in the RXRX Form 144 filing?

The selling security holder is Blake C. Borgeson, associated with Recursion Pharmaceuticals Inc., who is reporting planned sales and recent past sales of Class A common stock under Form 144.

How many RXRX shares has Blake C. Borgeson sold in the past three months?

The filing reports sales of 100,000 Class A shares over three transactions: 30,000 shares on May 5, 2026, 30,000 shares on June 2, 2026, and 40,000 shares on July 7, 2026, totaling $374,500.00 in proceeds.

At what prices were the recent RXRX Class A share sales made?

The reported aggregate amounts were $105,600.00 for 30,000 shares on May 5, 2026, $110,400.00 for 30,000 shares on June 2, 2026, and $158,500.00 for 40,000 shares on July 7, 2026.

What is the origin of the RXRX shares being sold by Blake C. Borgeson?

The shares are identified as founders shares acquired from the issuer as compensation on September 19, 2017, according to the Form 144 disclosure.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	30000	97500.00	524677865	08/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	09/19/2017	Founders Shares	Issuer			30000	09/19/2017	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Blake C. Borgeson 41 S Rio Grande Street Salt Lake City UT 84101	Class A	05/05/2026	30000	105600.00
Blake C. Borgeson 41 S Rio Grande Street Salt Lake City UT 84101	Class A	06/02/2026	30000	110400.00
Blake C. Borgeson 41 S Rio Grande Street Salt Lake City UT 84101	Class A	07/07/2026	40000	158500.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)